The effects of TRX suspension training on sarcopenic biomarkers and functional abilities in elderlies with sarcopenia: a controlled clinical trial
Authors:
Open Access
- 26 February 2024
- journal article
- research article
- Published by Springer Nature in BMC Sports Science, Medicine and Rehabilitation
- Vol. 16 (1) , 1-13
Abstract
Background: Sarcopenia is an age-related progressive loss of muscle mass and strength that can be modulated by resistance training. This study aimed to investigate the effects of TRX Suspension Training (TST) on serum levels of neuromuscular and growth factors and functional indices in elderly men with sarcopenia, an age-related condition characterized by progressive muscle mass and strength loss.Methods: Nineteen sarcopenic elderly men (age = 74.87 ± 4.58 years) were randomly assigned into two groups, the TST group (n = 10) and the control group (n = 9). Serum concentrations of regulatory muscle markers, anthropometric and body composition indices, and functional tests were evaluated at baseline and after 8 weeks. The training protocol consisted of eight weeks of TRX exercises, with three weekly sessions.Results: After 8 weeks of training, growth factors such as Follistatin (FST) (P = 0.001), 22 kDa C-terminal agrin fragment (CAF) (P = 0.031), and growth differentiation factor 15 (GDF15) (P = 0.049) increased significantly in the training group in comparison to the control group and Myostatin (MSTN) (P = 0.002) had a significant decrease. However, there was no significant difference in ASMM/m2 (P = 0.527), SMM/m2 (P = 0.621), or Body fat mass (P = 0.433) within or between groups. In addition, the TRX Suspension Training had a significant effect on the functional tests and improved gait speed (P = 0.037), chair stand (P = 0.016), and TUG (P = 0.016) as well as Handgrip strength (P = 0.035).Conclusion: Our findings highlight the efficacy of TRX Suspension Training in enhancing the serum levels of muscle growth factors and functional capacities among elderly individuals with sarcopenia. Therefore, considering the ongoing COVID-19 pandemic, this protocol can prove beneficial for this demographic group.Trial registry: Iranian Registry of Clinical Trials identifier: IRCT20230727058944N1, prospectively registered 20-09-2023,https://en.irct.ir/trial/71635Keywords
This publication has 55 references indexed in Scilit:
- Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathwaysCellular and Molecular Life Sciences, 2014
- Biomarkers of muscle quality: N‐terminal propeptide of type III procollagen and C‐terminal agrin fragment responses to resistance exercise training in older adultsJournal of Cachexia, Sarcopenia and Muscle, 2013
- Adaptive Induction of Growth Differentiation Factor 15 Attenuates Endothelial Cell Apoptosis in Response to High Glucose StimulusPLOS ONE, 2013
- Sustained Elevation of Circulating Growth and Differentiation Factor-15 and a Dynamic Imbalance in Mediators of Muscle Homeostasis Are Associated With the Development of Acute Muscle Wasting Following Cardiac Surgery*Critical Care Medicine, 2013
- C-terminal Agrin Fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junctionExperimental Gerontology, 2013
- Resistance training induced increase in muscle fiber size in young and older menEuropean Journal of Applied Physiology, 2012
- A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approachAge and Ageing, 2011
- Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activinAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein ActivationCirculation Research, 2006
- A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home AdmissionJournal of Gerontology, 1994